Results 61 to 70 of about 40,229 (203)
Deep-seated infections caused by AmpC-producing Enterobacterales (AmpC-E) pose challenges due to high bacterial burdens, altered pharmacokinetics, and the inoculum effect.
Nicole Slain +2 more
doaj +1 more source
A presumed case of pulmonary alveolar proteinosis with clinical deterioration was ultimately identified at autopsy as pneumonic‐type pleomorphic carcinoma. This case highlights the diagnostic overlap between diffuse lung diseases and the risk of anchoring bias in critically ill patients.
Dakota Wheeler +3 more
wiley +1 more source
Abstract Background Recent European Society of Clinical Microbiology and Infection and Australasian Society of Infectious Diseases Clostridioides difficile infection (CDI) management guidelines endorse the addition of intravenous tigecycline in patients who are progressing to fulminant infection.
Emma Bishop +5 more
wiley +1 more source
Cefepime plus enmetazobactam represents a breakthrough novel combination of a β-lactam antibiotic and a β-lactamase inhibitor, which demonstrates extensive antibacterial activity against a wide range of both gram-positive and gram-negative bacteria.
Raja Chakraverty +2 more
doaj +1 more source
Nine ant taxa were identified in a Brazilian hospital, with Tapinoma melanocephalum and Dorymyrmex brunneus being the most abundant. Eighty‐five percent of collected ants yielded detectable bacterial growth, including clinically relevant genera such as Acinetobacter, Pseudomonas, Escherichia coli and Pluralibacter.
Luana Biggi Souza +10 more
wiley +1 more source
The protocol of a multi‐site, double‐blinded, clustered randomized controlled trial (cRCT) with a binary outcome of the presence of viable presumptive ESKAPEE pathogens on surfaces in and around hospital sinks is to be implemented in two Bolivian hospitals.
Lindsay B. Saber +14 more
wiley +1 more source
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales [PDF]
Cefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of ...
Bhowmick, Tanaya +6 more
core +1 more source
In this pediatric abdominal solid organ transplant cohort, preservation fluid‐related infections were rare but occurred in infant liver transplant recipients whose preservation fluid cultures grew pathogenic organisms. These findings suggest that routine bacterial preservation fluid cultures may be most useful for identifying clinically significant ...
Hassan A. Jamal +5 more
wiley +1 more source

